A commercial health plan does not answer to the local coverage determination that binds a Medicare Administrative Contractor in its jurisdiction. It writes its own medical policy, and that policy can designate a specific skin substitute, also called a cellular and tissue-based product, as investigational or unproven for every use except a narrow set of clinical criteria the plan itself defines. The result is exposure a Medicare-only practice has not seen before: prospective denials and post-payment recoupment on claims already paid. A commercial audit treated like a Medicare audit routes the practice's strongest arguments to the wrong appeal path, because the governing rules come from the payer's contract and state law, not from the ladder that governs a Unified Program Integrity Contractor (UPIC) audit of a wound care practice.

How A Commercial Medical Policy Differs From A Medicare LCD

UnitedHealthcare's own commercial medical policy on skin and soft tissue substitutes, Policy Number 2026T0592HH, effective August 1, 2026, states that named products including EPIFIX and GRAFIX are "unproven and not medically necessary for all other indications" once the claim falls outside the specific wound type, circulation status, and prior-treatment criteria the policy lists for diabetic foot ulcers. Medicare's local coverage determinations set comparable clinical criteria within a Medicare Administrative Contractor's jurisdiction, but a commercial plan's medical policy is the plan's own document, not a government contractor's public rule.

Appeal Rights Run Through The Provider Agreement, Not The Medicare Ladder

Medicare gives a provider a statutory appeal ladder: redetermination, reconsideration, an administrative law judge hearing, and judicial review, each with its own deadline set by federal regulation. A commercial payer's appeal process is a creature of the provider agreement and of whatever state insurance law applies to that plan, with no comparable statutory ladder. One documented example: Blue Cross Blue Shield of Michigan's practitioner appeal process runs through addenda to its practitioner participation agreements, with a written complaint, a plan response, and an informal conference available on request. A wound care practice facing a skin substitute denial has to read its own participation agreement and the applicable state insurance law before assuming a Medicare-style deadline applies.

Documentation Standards And The Mechanics Of Recoupment

A commercial payer's post-payment review tests the claim against that payer's own medical policy criteria, not an LCD: wound measurements, glycated hemoglobin values, weeks of prior standard care, and a properly maintained signature log tying each debridement or graft application to a signed, dated note. Medicare recoups an overpayment through a uniform administrative offset process set by federal regulation. A commercial payer recoups through the offset mechanics its own provider agreement describes, and the notice period and lookback window the plan must observe come from the state insurance law that applies to it, which varies by jurisdiction in a way the Medicare process does not. That window should not be assumed to match a Medicare lookback period, and the same documentation discipline applies to compression documentation for a venous leg ulcer billed to the same plan.

Escalation Risk: Credentialing Review And Network Termination

A pattern of adverse skin substitute audit findings carries an escalation risk distinct from Medicare's threat of program exclusion. Repeated findings can surface at the plan's next credentialing review and support a termination for cause under the participation agreement, a contractual remedy, not a government debarment action. A provider terminated for cause loses access to that plan's members and may face the finding again at a different payer's next credentialing review. The same billing pattern can also draw a parallel False Claims Act theory, a separate track that a commercial resolution does not settle.

A commercial payer audit of skin substitute claims is a contract dispute dressed as a medical review, and the provider agreement is the only place the provider's appeal rights actually live.

Why Early Legal Counsel Is Critical

It is critical that wound care providers promptly retain experienced healthcare defense counsel upon receiving a commercial payer's skin substitute denial, audit notice, or recoupment demand. Early legal intervention can identify which document governs the provider's rights, the participation agreement or a state statute, before a deadline is missed. Counsel can also preserve the record the plan's medical policy requires and communicate with the payer's audit unit on the provider's behalf. Delaying representation can foreclose an appeal step that was only available earlier in the plan's own process.

How Health Law Alliance Can Help

Health Law Alliance has handled 5,000+ matters across healthcare regulatory and audit defense over 25+ years, including commercial payer audits of skin substitute and cellular and tissue-based product claims. If your practice has received a commercial payer denial, audit notice, or recoupment demand tied to skin substitute claims, contact Health Law Alliance's wound care audit defense attorneys for a free, confidential consultation.